Organoid Cell Lines
Technology
The Cancer Organoids project at The Wellcome Sanger Institute involves the derivation, culture, banking and genetic validation of organoid cell lines produced from tumour samples taken from patients during surgical resection. The main aim of this project is to produce high quality, validated organoid models that reflect the cellular and genetic heterogeneity of prevalent human cancers.
The Technology consists of:
- 230+ high quality, validated organoid models that reflect the cellular and genetic heterogeneity of prevalent human cancer
- Developed as part of Project Gro (https://www.sanger.ac.uk/collaboration/organoids-projectgro/) and Human Cancer Model Initiative (HCMI) aiming to derive and genetically characterise organoid cell models from prevalent human carcinomas to produce high quality organoid models suitable for a vast range of downstream scientific research.
- Patient-derived next-generation organoid cancer models were derived from cancer tumour samples taken during surgical resection, expanded and cryobanked.
- Each model has passed strict quality controls to ensure successful culturing.
- Available organoids models include: colon, oesophageal, breast, ovarian, pancreatic, gastric, mesothelial; the derivation is still ongoing.
- Sanger continues to submit organoids to ATCC for distribution to the scientific community.
- The Wellcome Sanger Institute is offering non-exclusive licences on these cell lines, subject to resolution of third party IP issues. Please contact us to express your interest.
Advantages
- The organoid cancer models are highly characterised.
- Characterisation data will be open-access and freely available through EGA (https://ega-archive.org/studies/EGAS00001002221) and cell passport models (https://cellmodelpassports.sanger.ac.uk/passports?model_type=organoid)
- Donor consent expressly allows for commercial exploitation.
Applications/Context
Organoid cancer models represent a novel in vitro platform for basic biological research and potential applications in drug testing and molecular medicine.
Use in various applications can complement existing experimental models. Potential applications include:
- Development of platforms for drug screening
- Immuno-oncology assays
- Compounds’ safety and toxicity testing
Contact
If you need help or have any queries, please contact us using the details below.
